Affiliation:
1. Service de Microbiologie, CHU Côte de Nacre, Caen
2. Unité des Agents Antibactériens, Institut Pasteur, Paris, France
Abstract
ABSTRACT
Bacillus clausii
SIN is one of the four strains of
B. clausii
composing a probiotic administered to humans for the prevention of gastrointestinal side effects due to oral antibiotic therapy. The strain is resistant to kanamycin, tobramycin, and amikacin. A gene conferring aminoglycoside resistance was cloned into
Escherichia coli
and sequenced. The gene, called
aadD2
, encoding a putative 246-amino acid protein, shared 47% identity with
ant(4
′
)-Ia
from
Staphylococcus aureus
, which encodes an aminoglycoside 4′-
O
-nucleotidyltransferase. Phosphocellulose paper-binding assays indicated that the gene product was responsible for nucleotidylation of kanamycin, tobramycin, and amikacin. The
aadD2
gene was detected by DNA-DNA hybridization in the three other strains of the probiotic mixture and in the reference strain
B. clausii
DSM8716, although it did not confer resistance in these strains. Mutations in the sequence of the putative promoter for
aadD2
from
B. clausii
SIN resulted in higher identity with consensus promoter sequences and may account for aminoglycoside resistance in that strain. The
aadD2
gene was chromosomally located in all strains and was not transferable by conjugation. These data indicate that chromosomal
aadD2
is specific to
B. clausii
.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献